TAP
GILD icon

Tounjian Advisory Partners’s Gilead Sciences GILD Stock Holding History

Tounjian Advisory Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.33K Buy
+18
New +$2.37K ﹤0.01% 563
2025
Q3 		– Sell
-3,724
Closed -$417K – 189
2025
Q2 		$417K Sell
3,724
-58
-2% -$6.17K 0.08% 199
2025
Q1 		$424K Buy
+3,782
New +$390K 0.08% 199

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Tounjian Advisory Partners's GILD Position: Q2 2026 in Review

Tounjian Advisory Partners opened a new position in Gilead Sciences (GILD) in Q2 2026: 18 shares worth $2.33K. The stake represents ﹤0.01% of the portfolio and ranks #563 among its holdings. This is a return to the name: Tounjian Advisory Partners previously reported a position in GILD as recently as Q2 2025.

Tounjian Advisory Partners first reported a position in GILD in Q1 2025 and has held it in 3 quarters since. The position peaked at $424K in Q1 2025. 2,292 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Tounjian Advisory Partners held 18 shares of Gilead Sciences worth $2.33K as of Q2 2026.
  • Gilead Sciences was a new Tounjian Advisory Partners position in Q2 2026.
  • Gilead Sciences made up ﹤0.01% of Tounjian Advisory Partners's portfolio in Q2 2026, its #563 holding.
  • Tounjian Advisory Partners first reported a position in Gilead Sciences in Q1 2025 and has held it in 3 quarters since.
  • Tounjian Advisory Partners's Gilead Sciences position peaked at $424K in Q1 2025.
  • 2,292 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Tounjian Advisory Partners's 13F filing for Q2 2026, filed 7 Aug 2026.